News & Updates
Filter by Specialty:
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
In the treatment of patients with mild-to-moderate COVID-19, adding fluvoxamine to favipiravir does not appear to prevent disease progression or improve certain outcomes, according to the results of an open-label study.
Add-on fluvoxamine of no benefit in mild-to-moderate COVID-19
07 Jul 2023
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
Use of renin-angiotensin system (RAS) inhibitors results in improved clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF) and advanced kidney disease, a study has shown.
RAS inhibitors proven beneficial in HFrEF with advanced kidney disease
06 Jul 2023
More evidence for COVID-19 vaccine safety in kids
COVID-19 vaccines can be safely administered in children, with a recent study showing that out of the numerous health outcomes monitored in near real time, the safety signal identified was for only myocarditis or pericarditis.
More evidence for COVID-19 vaccine safety in kids
05 Jul 2023
ADHD meds emerge as preferred option for reducing self-harm risk in BPD
For individuals with bipolar disorder (BPD), attention-deficit/hyperactive disorder (ADHD) medications help lower the risk of suicidal behaviour, according to data from a comparative effectiveness research study.
